We use cookies to understand how you use our site and to improve your experience. Please refer to our Terms and Conditions and Privacy Policy for more information about the cookies we use and how we protect your privacy.
"Acute GVHD Diagnostics, Leveraging Biomarkers in Patient Treatment: Clinical Case Studies"
Presented by Dr. James Ferrara, Ichan School of Medicine at Mount Sinai
2019 TCT Meetings
Wednesday, February 20, 1:30 - 2:30 PM
George R. Brown Convention Center, Houston TX, Room GRB 382A
Join us in Houston!
The clock is ticking to reserve your seat at the aGVHD Product Theater.
00 Days |
00 Hrs |
00 Min |
00 Sec |
Agenda
Join Dr. James Ferrara as he presents information on Viracor’s aGVHD Algorithm testing for Pre-Symptomatic, Symptom Onset, and Post-Treatment Hematopoietic Cell Transplant patients (HCT) at high risk for non-relapse mortality and acute graft-versus-host disease. Dr. Ferrara’s presentation will start with an introduction to the biology of the biomarkers utilized in the aGVHD Algorithm testing (REG-3α and ST2), explaining how they act as a “liquid biopsy” of the GI tract.
Dr. Ferrara will then dive into three different clinical scenarios where utilization of the aGVHD Algorithm Tests could predict non-relapse mortality and aGVHD. While reviewing example reports for each of the clinical scenarios, Dr. Ferrara will also recommend the desired approach for treatment. Finally, in the Q&A section we encourage the participants to engage directly with Dr. Ferrara and Viracor’s Executive Science Team to ask questions about the aGVHD Algorithm Tests.
WHAT: aGVHD Presentation and Q&A
WHO: Dr. James Ferrara
Ichan School of Medicine at Mount Sinai
WHEN: Wednesday, Feb. 20, 1:30 - 2:30 PM
WHERE: 2019 TCT Meetings in Houston, Tx
George R. Brown Convention Center, Room GBR 382A
(Near the skywalk connecting the GRB CC to the Hilton)
About Dr. James Ferrara
Ward-Coleman Chair in Cancer Medicine
Professor of Pediatrics & Medicine, Ichan School of Medicine at Mount Sinai
Dr. James Ferrara is a physician-scientist whose clinical and research career has focused on the immunology of bone marrow transplantation (BMT), particularly its major complication graft versus host disease (GVHD). Using trailblazing proteomic techniques, his team has identified and validated unexpected biomarkers for skin, gut and steroid-resistant GVHD. He has created exceptionally large and informative biorepositories and then mined them to meld these biomarkers into the first algorithm that predicts response to treatment and that can guide GVHD therapy. Dr. Ferrara’s pioneering mechanistic studies have illuminated unexpected interactions between the innate and adaptive immune systems and have led to both conceptual breakthroughs and the discovery of novel therapeutic targets. A superb clinician and world-class clinical investigator, his decades-long focus on GVHD has significant potential impact in making BMT safer and more effective for all patients.
Dr. Ferrara graduated Cum laude from Georgetown Medical School and then completed his pediatric residency and fellowship at Boston’s Children’s and the Dana-Farber Cancer Institute. After 19 years he went to the University of Michigan to direct the combined adult and pediatric BMT program. The Icahn School of Medicine at Mount Sinai recruited Dr. Ferrara in 2014 to become the Ward-Coleman professor of Cancer medicine and to direct the Center for Translational Research in Hematologic Malignancies.
REGISTRATION
Join us February 20th, 1:30 - 2:30 PM. Snacks and refreshments will be served.
2019 TCT Meetings, George R. Brown Convention Center, Houston TX
GRB Room 382A (Near the skywalk connecting the GRB CC to the Hilton)
After submitting the registration form, you will receive a confirmation at the email address you provided.
If you do not receive a confirmation, please email DanaiWells@viracor-eurofins.com
Look for aGVHD Oral Presentation and Abstracts at 2019 TCT Meetings
Send your aGVHD testing to a lab that's leading the industry in testing research and development. Learn how Viracor and our partners are taking aGVHD clinical diagnostic testing to the next level.
A Prospective Multi-Center Study of the Natural History of BK Viremia and Host Immune Response in Children after Allogeneic Hematopoietic Cell Transplant
Presented by Benjamin Laskin
Oral Abstract - Session B
Pediatric Transplantation and Cell Therapy
Wednesday, February 20
4:45 PM
Stability of CMV CD4 and CD8 T Cell Responses in Seropositive Donors and Evaluation of Immunosuppressed Patients
Presented by Michelle Altrich
Poster Session II, #553
Saturday, February 23
6:45 PM – 7:45 PM
George R. Brown Convention Center - Level 3 - Hall B
Acute Graft-Versus-Host Disease (aGVHD, Non-Relapse Mortality) Risk Prediction Assay: Validation and Initial Reference Lab Experience
Presented by Mauricio Miralles
Poster Session I, #319
Wednesday, February 20
6:45 PM – 7:45 PM
George R. Brown Convention Center - Level 3 - Hall B
Detection of CMV Antiviral Resistance Mutations to Letermovir in Patients Using a Validated Clinical Sequencing Assay
Presented by James Grantham
Poster Session II, #514
Saturday, February 23
6:45 PM – 7:45 PM
George R. Brown Convention Center - Level 3 - Hall B
How does biomarker testing predict risk of aGVHD & non-relapse mortality?
Learn about the First aGVHD Algorithm with Clinical Cutoffs for HCT Patients
Helping healthcare providers definitively identify patients at risk, delivering actionable data that could improve outcomes.
About Viracor's aGVHD Biomarker Testing
PRE-SYMPTOMATIC
Using the pre-symptomatic algorithm with a blood sample taken approximately 7 days after transplant, physicians can identify a patient at high risk for severe aGVHD and NRM, when the patient is not actively displaying symptoms, and can potentially adjust therapy to mitigate identified risks.
SYMPTOMATIC ONSET
With the symptomatic onset algorithm, results predict the pathology of some of the most severe forms of aGVHD — for example, presentation in the gastrointestinal tract — before disease progression becomes serious.
New to Viracor?
With over 30 years of specialized expertise in infectious disease, immunology and allergy testing for immunocompromised and critical patients, Viracor is committed to helping medical professionals, transplant teams, reference labs and biopharmaceutical companies get results faster, when it matters most.
We would be honored to be your diagnostic testing partner. For more information and to set up an account, please click on the button below.
SET UP AN ACCOUNTThis promotional activity is provided by Viracor and is not certified for continuing education credit. The content of this Product Theater and opinions expressed by presenters are those of the sponsor or presenters and not of the TCT Meetings, ASBMT or CIBMTR.
Connect with us